At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 424 enrolled
Drug / intervention
Lebrikizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab and Placebo for Atopic Dermatitis. Completed, enrolled 424 participants across 94 sites in 10 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, Estonia, France, Latvia, Lithuania, Poland, South Korea, Spain, United States
CollaboratorsDermira, Inc.
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedOct 2019
Primary CompletionJun 2021
Study CompletionMay 2022
TodayJul 2026
First PostedOct 31, 2019
Enrollment StartSep 24, 2019
Primary CompletionJun 21, 2021
Study CompletionMay 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.7 years ago
Interventions
Lebrikizumabbiological
Subcutaneous injection
Placeboother
Subcutaneous Injection